Instrument Inactif

Autres langues e-therapeutics plc London S.E.

Actions

ETX

GB00B2823H99

Recherche biotechnologique et médicale

Autres langues

03/09	Tangram Therapeutics Announces Progression to Patient Cohorts in Phase 1/2 RESTORE-MASH Trial of TGM-312
03/09	Tangram Therapeutics Announces the Appointment of Sonya Montgomery as Chief Development Officer
05/03	Tangram Therapeutics Announces First Participant Dosed in Phase 1/2 Restore-Mash Trial Of TGM-312
26/11	Tangram Therapeutics Submits Clinical Trial Application for Phase 1/2 Study of TGM-312, A Novel Investigational RNAi MASH Candidate
10/07/25	E-therapeutics plc De-Risks Clinical Path for Galomic Candidate ETX-312 with Positive Non-Clinical Data
21/05/25	E-therapeutics plc Reports Earnings Results for the Full Year Ended January 31, 2025
07/05/25	E-therapeutics Presents New Data Supporting ETX‑312 as a Differentiated and Disease-Modifying Near-Clinic Treatment for MASH
07/05/25	E-therapeutics plc Presents New Data Supporting ETX-312 as a Differentiated and Disease-Modifying Near-Clinic Treatment for MASH
05/02/25	E-therapeutics veröffentlicht präklinische Daten zu ETX-148 auf dem EAHAD 2025
05/02/25	E-therapeutics to Present Preclinical Data on ETX-148 at EAHAD 2025
31/10/24	E-therapeutics plc Reports Earnings Results for the Half Year Ended July 31, 2024
31/10/24	E-therapeutics Announces Business Updates and Interim Results
16/07/24	E-therapeutics plc, Results of Annual General Meeting and Appointment of Jeremy Punnett to the Board of Directors
16/07/24	E therapeutics : Results of Annual General Meeting and Appointment of Jeremy Punnett to the Board of Directors
03/07/24	E-therapeutics announces completion of £28.90 million fundraise
06/06/24	E therapeutics : Annual Report for the year ended 31 January 2024
06/06/24	E therapeutics : Pipeline update and final results for the year ended 31 January 2024
06/06/24	E-therapeutics plc Reports Earnings Results for the Full Year Ended January 31, 2024
23/05/24	Lord David Prior Appointed as Chair of e-therapeutics’ Board of Directors
23/05/24	E therapeutics : Lord David Prior Appointed as Chair of e‑therapeutics' Board of Directors
23/05/24	E therapeutics : Lord David Prior Appointed as Chair of e‑therapeutics plc Board of Directors
30/09/22	E-therapeutics: Fundraise of £13.5 million